Thymic 18F-fluorodeoxyglucose uptake on positron emission tomography scanning after doxorubicin, bleomycin, vincristin and dacarbazine chemotherapy and highly-active antiretroviral therapy in HIV-associated Hodgkin's disease in an adult.
Lee
Siow Ming
SM
Buchler
Tomas
T
Bomanji
Jamshed
J
Ramsay
Alan
A
Edwards
Simon G
SG
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001761:Bleomycin / Q000627:therapeutic use*; D003606:Dacarbazine / Q000627:therapeutic use*; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use*; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods; D013950:Thymus Gland / Q000378:metabolism; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D000903:Antibiotics, Antineoplastic; D019788:Fluorodeoxyglucose F18; D001761:Bleomycin; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin